Biolidics Limited (8YY.SI)
- Previous Close
0.0120 - Open
0.0100 - Bid 0.0110 x --
- Ask 0.0120 x --
- Day's Range
0.0100 - 0.0120 - 52 Week Range
0.0100 - 0.0190 - Volume
59,800 - Avg. Volume
954,911 - Market Cap (intraday)
9.339M - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Apr 26, 2024 - Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Biolidics Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions. The company operates through Cancer, Infectious Diseases, and Laboratory Services segments. It provides Covid-19 PCR testing kits. The company offers ClearCell FX1 System, an automated device that separates and enriches cancer cells from blood; and antigen and antibody test kits, as well as laboratory services. It serves academic and research institutes, hospitals, and laboratories in Singapore, China, Hong Kong, Japan, the United States, and other European Union countries. The company was incorporated in 2009 and is based in Singapore.
www.biolidics.comRelated News
Performance Overview: 8YY.SI
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 8YY.SI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 8YY.SI
Valuation Measures
Market Cap
9.34M
Enterprise Value
11.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.41
Price/Book (mrq)
--
Enterprise Value/Revenue
8.50
Enterprise Value/EBITDA
-5.24
Financial Highlights
Profitability and Income Statement
Profit Margin
-182.81%
Return on Assets (ttm)
-45.57%
Return on Equity (ttm)
--
Revenue (ttm)
1.36M
Net Income Avi to Common (ttm)
-2.49M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
183k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.84M
Company Insights: 8YY.SI
8YY.SI does not have Company Insights